HAT1 and pancreatic neoplasm: As an oncogene, HAT1 is overexpressed and related to poor prognosis in a variety of solid tumors, such as HCCs (Jin et al., 2017), nasopharyngeal carcinoma (Miao et al., 2018), and pancreatic cancer (Fan et al., 2019), and can be a therapeutic target (Carafa et al., 2018).